摘要
目的:探讨质子泵抑制剂(PPI)、组胺-2受体拮抗剂(H2RA)的使用与胰腺癌发生风险的关系。方法:检索2019年7月31日前公开发表的有关PPI及H2RA与胰腺癌发病风险有关的临床试验的相关文献。通过纳入和排除标准筛选后采用纽卡斯尔-渥太华量表进行质量评分,采用Stata12.0进行Meta分析。结果:最终纳入8篇文献共551137例患者,其中胰腺癌患者21015例,包括6个病例对照研究,2个队列研究。Meta分析结果显示:PPI及H2RA可增加胰腺癌发病风险,OR值分别为1.61(95%置信区间1.11-2.32)及1.26(95%置信区间1.02-1.57)。结论:使用PPI及H2RA可能增加胰腺癌发生风险,因此需严格按照适应症慎重开具处方,避免长时间、大剂量使用。
Objective:To assess the risk of developing pancreatic cancer in patients who used Proton pump inhibitors(PPI)and histamine-2-receptor antagonist(H2RA).Methods:A literature search was performed from inception through July 31,2019.Studies that reported odds ratio comparing the risk of pancreatic cancer in patients who receiving PPI or H2 RA versus who not receiving treatments were included.Results:After screening abstracts from the searching methods,six case-control studies and two cohort studies were included in the analysis,with total 551137 patients including 21015 patients with pancreatic cancer.Compared to patients without taking treatment,the pooled OR of developing pancreatic cancer in patients who received PPI was1.61(95%CI 1.11-2.32)and H2 RA was 1.26(95%CI1.02-1.57).Conclusion:Using of PPI and H2RA probably increased the risk of pancreatic cancer development.Therefore,prescription carefully following the indications is necessary.
作者
庄燕妍
陈文博
黄娴娴
杨巍
黄凤婷
张世能
ZHUANG Yan-yan;CHEN Wen-bo;HUANG xian-xian;YANG Wei;HUANG Feng-ting;ZHANG Shi-neng(Department of gastroenterology,Sun Yat-sen Memorial Hospital,Sun Yat-sen University,Guangzhou,Guangdong,510120;Department of Geratology,the First Affiliated Hospital of Medical College of Southern University of Science and Technology the Second Clinical Medical College of Ji'nan University Shenzhen People's Hospital,Shenzhen,Guangdong)
出处
《岭南急诊医学杂志》
2019年第5期462-466,共5页
Lingnan Journal of Emergency Medicine
基金
广东省科技计划项目（2016A020215060）
